Comparative Pharmacology
Head-to-head clinical analysis: BYFAVO versus TRIAZOLAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BYFAVO versus TRIAZOLAM.
BYFAVO vs TRIAZOLAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective adenosine A2A receptor antagonist; promotes wakefulness by blocking the inhibitory effects of adenosine on arousal-promoting neurons in the brain.
Triazolam is a benzodiazepine that binds to GABA-A receptors at the alpha-1 subunit, potentiating the inhibitory effects of GABA and increasing chloride ion influx, leading to neuronal hyperpolarization and sedation.
For induction and maintenance of general anesthesia: 0.3 mg/kg intravenously over 30 seconds, followed by an infusion of 1.5 mg/kg/hour adjusted to effect. Additional boluses of 0.075 mg/kg may be given as needed.
0.125-0.25 mg orally once daily at bedtime; maximum 0.5 mg/day.
None Documented
None Documented
Clinical Note
moderateTriazolam + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Triazolam is combined with Fluticasone propionate."
Clinical Note
moderateTriazolam + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Triazolam."
Clinical Note
moderateTriazolam + Erythromycin
"The serum concentration of Erythromycin can be increased when it is combined with Triazolam."
Clinical Note
moderateTriazolam + Cyclosporine
Terminal elimination half-life is approximately 2-4 hours; clinical context: requires continuous infusion for sustained effect, as rapid clearance may lead to loss of efficacy.
1.5-5.5 hours (mean 2-4 hours) in healthy adults; prolonged in hepatic cirrhosis and elderly.
Renal excretion accounts for approximately 90% of the administered dose, with <5% as unchanged drug. Biliary/fecal elimination is minimal (<5%).
Primarily renal: approximately 80% as metabolites, less than 2% unchanged; biliary/fecal: minor (about 8-10%).
Category C
Category D/X
Benzodiazepine
Benzodiazepine
"The metabolism of Cyclosporine can be decreased when combined with Triazolam."